Incomplete Polyp Resection Often to Blame for PCCRC

At least 22% of post-colonoscopy colorectal cancer is likely related to incomplete polyp resection, researchers ...

AUGUST 6, 2025

DDW 2025 Expert Picks, Part 1

In part 1 of the DDW Expert Picks column, we review top abstracts from the ASGE program ...

JULY 24, 2025

White-Light Endoscopy for Cancer Detection, Capsule Endoscopy to Guide CD Treatment

This month, I focus on different endoscopic techniques that gastroenterologists might use, one for CRC detection in ...

JUNE 30, 2025

Mixed Results Seen for PREEMPT CRC Screening Test

The PREEMPT CRC study met its primary end points but with a lower magnitude of benefit than investigators had ...

JUNE 6, 2025

Structured Exercise Improves Survival in Stage II/III Colon Cancer

A structured exercise program after adjuvant chemotherapy in patients with high-risk stage II or III colon cancer ...

JUNE 4, 2025

Simple Patient Outreach Led to 50% Drop in CRC Mortality Rates

Offering flexible options for CRC screening doubled screening rates, cut cancer incidence by a third, halved ...

MAY 4, 2025

FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

The FDA has approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with ...

APRIL 16, 2025

FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C–mutated metastatic CRC.

JANUARY 24, 2025

Novel Stool-Based CRC Screening Test Yields Impressive Early Results

A stool-based test that combines biomarkers of CRC using an AI–driven algorithm showed high sensitivity for ...

JANUARY 17, 2025

Expert Picks From ACG 2024: Part 2

In this second installment of Expert Picks from ACG 2024, Brooks D. Cash, MD, FACG, discusses five colon- and ...

JANUARY 16, 2025

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase (Opdivo Qvantig, Bristol Myers Squibb) for an array of GI cancers.

JANUARY 8, 2025

FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer

The FDA granted accelerated approval to encorafenib with cetuximab and mFOLFOX6 for patients with mCRC.

JANUARY 2, 2025